Skip to main content
Premium Trial:

Request an Annual Quote

Agowa Buys Roche GS FLX System

NEW YORK (GenomeWeb News) – Genomics and DNA sequencing services company Agowa genomics has purchased a Roche Genome Sequencer FLX system, Roche said today.
The company, a subsidiary of LGC, said the new sequencer will support its expanded range of services and enable it to meet the growing market demand for higher throughput and capacity in sequencing projects.
The Berlin, Germany-based company offers de novo sequencing of prokaryotic and small eukaryotic genomes; completion of de novo sequencing including resolution of repeats and gap closure; analysis of metagenomes and transcriptomes, normalized cDNA methylation patterns, and pools of tagged fosmids and BACs; and targeted re-sequencing of amplicons and genotyping.
Agowa also said it will use the novel GS FLX Titanium reagents that Roche will launch this fall.
The company said its scientists will work with the new high-throughput sequencing technologies along with LGC’s corporate Research & Technology Division to develop new applications. Agowa also plans to expand its sequencing labs and employ new sequencing specialists and laboratory staff.
Financial terms of the agreement were not released.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.